Subscribe
The latest psychology and neuroscience discoveries.
My Account
  • Mental Health
  • Social Psychology
  • Cognitive Science
  • Psychopharmacology
  • Neuroscience
  • About
No Result
View All Result
PsyPost
PsyPost
No Result
View All Result
Home Exclusive Psychopharmacology Psychedelic Drugs Psilocybin

21-year-old man dies after jabbing pencil into his brain during psilocybin trip

by Eric W. Dolan
June 5, 2025
in Psilocybin
[Adobe Stock]

[Adobe Stock]

Share on TwitterShare on Facebook
Stay on top of the latest psychology findings: Subscribe now!

In a newly reported case, a 21-year-old Hispanic man in Texas died after stabbing himself in both eyes with a pencil during a bad psychedelic experience at home. The disturbing event, published in the American Journal of Ophthalmology Case Reports, provides a rare but sobering account of how the effects of psilocybin—the active compound in “magic mushrooms”—can, under certain conditions, result in tragic outcomes. The patient suffered severe brain damage after a pencil entered his skull through his eye socket, ultimately leading to his death despite intensive surgical care.

While psilocybin is being actively explored for its potential to treat mental health conditions like depression and post-traumatic stress disorder, the report underscores the need for greater awareness of potential psychiatric side effects, particularly when the substance is taken in unsupervised settings.

Psilocybin is a naturally occurring psychedelic compound found in certain species of mushrooms. Once ingested, it is converted into psilocin, which alters perception, mood, and thought patterns by stimulating serotonin receptors in the brain. Although it has a long history of traditional use, psilocybin has reemerged in recent years as a subject of modern medical interest due to its possible benefits in treating mood disorders.

Use of psilocybin has surged in the United States since 2019, following changes in public policy and a wave of scientific studies showing promising results. A recent analysis of five national datasets found that lifetime use of psilocybin among American adults rose from 10% in 2019 to over 12% in 2023. Past-year use jumped even more sharply, with a 44% increase among young adults and a 188% increase among those over 30. Despite growing interest in its therapeutic uses, psilocybin remains a federally controlled substance, and adverse events—though rare—can occur, particularly when consumed without medical guidance.

The young man described in the case report had a medical history that included attention-deficit/hyperactivity disorder and hypertension, which he managed with daily medications. He had no known history of depression, self-harm, or serious psychiatric illness. On the day of the incident, he returned home from work and consumed an unknown amount of psilocybin mushrooms.

Soon afterward, his behavior changed drastically. According to family members, he became agitated and paranoid—classic signs of a “bad trip.” Despite attempts by his stepfather and brother to calm him down, he broke a glass vase and began injuring himself. Then, in a horrific act, he placed a pencil upright on his desk and repeatedly drove his head onto it, penetrating both of his eye sockets. The pencil lodged deeply in the left eye and continued into his brainstem.

Emergency responders sedated and intubated him before transporting him to a hospital for advanced care. Initial brain scans showed that the pencil had punctured the pons, a region at the base of the brain vital for breathing and motor control. Imaging also revealed bleeding in the brain, skull fractures, and signs of vascular damage. Although the right eye had suffered a blowout fracture, the pencil had traveled through the left orbit and into the brainstem, causing a pontine hemorrhage and disruption of blood flow.

Over the next few days, a team of neurosurgeons and ophthalmologists worked to stabilize the patient and remove the foreign object. They used advanced imaging and surgical techniques, including vascular embolization and careful dissection, to extract the pencil. Despite these efforts, the patient’s condition worsened. He experienced ongoing brain swelling, additional bleeding, and increasing intracranial pressure. Eventually, he lost all brainstem reflexes and was declared brain dead five days after the injury.

While such a violent and tragic outcome is extremely rare, it is not entirely without precedent. Medical literature has documented other cases of self-inflicted injuries during psychotic episodes triggered by hallucinogens. In another recent case report, a 37-year-old man suffering from depression and alcohol abuse severed his penis with an axe after consuming psilocybin.

Most psilocybin-related adverse outcomes do not lead to death or severe injury. Psilocybin is generally considered to have a low risk of addiction and physical toxicity, but “bad trips” can lead to anxiety, confusion, hallucinations, and psychosis-like symptoms. One survey of over 1,900 users found that while the majority of “bad trips” resolved without medical intervention, 2.6% of respondents reported physically aggressive behavior, and 2.7% sought emergency care, while 11% acknowledged putting themselves or others at risk during the experience.

Although some might be tempted to draw broad conclusions from this single case, it is important to understand the nature and role of case reports in medicine. Case reports are detailed descriptions of unusual or novel clinical events involving one patient. They do not establish cause and effect or generalize to larger populations. However, they are valuable for identifying potential safety concerns, generating hypotheses for further research, and alerting clinicians to rare but serious risks. In this instance, the report highlights the potential dangers of unsupervised psychedelic use, particularly in individuals with unknown or latent vulnerabilities to psychiatric symptoms.

The patient’s history does not include any known mental illness or previous self-injurious behavior. However, the report notes that his biological father died by suicide, suggesting a possible hereditary vulnerability. This is consistent with existing concerns in the scientific literature that psychedelic substances may pose higher risks for individuals with a personal or family history of psychiatric illness.

More broadly, the case emerges at a time when public and scientific interest in psychedelics is at an all-time high. While early clinical trials have shown that psilocybin may help treat major depression and post-traumatic stress disorder, these results have come from structured settings with professional oversight, careful screening, and psychological support before, during, and after the experience. In contrast, recreational use—or self-medication without clinical guidance—can involve unknown doses, uncontrolled environments, and little preparation or safety planning.

The report, “Self-Inflicted Transorbital Intracranial Foreign Body Following Ingestion of Hallucinogenic Psilocybin Mushrooms,” was authored by Abigail M. Blanton, Pooja Parikh, Scott Zhou, Mohamed Mohamed, Rafael L. Ufret-Vincenty, and Ronald Mancini.

RELATED

Scientists reveal how DMT alters brain activity and consciousness by lowering control energy
Ketamine

Psychedelics alter neurochemical signals tied to hunger and mood in the hypothalamus

July 24, 2025

Researchers have discovered that psilocybin—but not ketamine—triggers widespread changes in neuropeptide-related genes in the rat hypothalamus. These findings may help explain how psychedelics influence mood, appetite, and stress responses through deep brain systems.

Read moreDetails
Cognitive tests suggest psilocybin impairs thinking—but the tests may not tell the full story
Cognitive Science

Cognitive tests suggest psilocybin impairs thinking—but the tests may not tell the full story

July 21, 2025

People under the influence of psilocybin perform more slowly on tasks measuring attention and executive function. But a new study suggests the problem might not be the drug—it might be the traditional lab tests used to assess cognition.

Read moreDetails
Some dark personality traits may help buffer against depression, new psychology research suggests
Mental Health

Psilocybin-assisted therapy linked to reduced depression in people with bipolar disorder, small study finds

June 17, 2025

A pilot study involving psilocybin-assisted therapy found possible antidepressant effects for people with bipolar II disorder. The treatment appeared well-tolerated, with no signs of mania or psychosis, offering cautious optimism for future bipolar depression research.

Read moreDetails
Psilocybin from “magic” mushrooms weakens the brain’s response to angry faces
Addiction

Single-dose psilocybin therapy shows promise for reducing alcohol consumption

June 15, 2025

Early results from a pilot study indicate that psilocybin-assisted therapy could be linked to lower alcohol consumption and improved psychological outcomes, though larger controlled trials are needed to determine whether the psilocybin itself is responsible for these changes.

Read moreDetails
Psilocybin appears to have a uniquely powerful relationship with nature relatedness
Neuroimaging

Psilocybin induces large-scale brain network reorganization, offering insights into the psychedelic state

June 14, 2025

A new study using high-resolution EEG reveals that psilocybin dramatically alters brain connectivity in rats. The psychedelic induced dose-dependent changes in network organization, disrupting normal patterns of neural communication and suggesting rodents may be viable models for studying altered consciousness.

Read moreDetails
Meta-analysis highlights potential of psilocybin therapy for treatment-resistant depression
Depression

Psilocybin therapy shows similar benefits for patients with and without recent antidepressant use

June 11, 2025

A new study finds that individuals with treatment-resistant depression experienced similar improvements from psilocybin-assisted psychotherapy whether or not they had recently discontinued antidepressant medications.

Read moreDetails
Clinical psychologists appear to have cautiously favorable attitudes toward psychedelic-assisted mental health treatments
Psilocybin

Only a specific dose of psilocybin induces lasting antidepressant-like effects, study suggests

May 27, 2025

A recent study found that a single moderate dose of psilocybin produced lasting antidepressant-like effects in rats, while higher doses led to unwanted side effects. The findings highlight the importance of optimal dosing.

Read moreDetails
Psilocybin and escitalopram produce antidepressant effects via distinct brain mechanisms, study suggests
Depression

Psilocybin and escitalopram produce antidepressant effects via distinct brain mechanisms, study suggests

May 25, 2025

A new study using brain scans found that psilocybin and escitalopram reduce depression symptoms through different neural mechanisms. While escitalopram dampened emotional brain activity, psilocybin preserved or slightly increased it, suggesting distinct pathways to recovery.

Read moreDetails

STAY CONNECTED

LATEST

How psychopathy connects alexithymia to decisions that sacrifice others

The psychology of belief explains America’s ongoing war with Darwin

Sugar addiction is real, according to these scientists

Narcissism is associated with higher aggression in combat athletes, study finds

Depressed individuals who feel stigmatized are more likely to contemplate suicide

Fascinating new research reveals how sexual desire shapes long-term partner preferences

Surprising Alzheimer’s breakthrough: Sugar in neurons might be the missing link

Lucid dreamers report reduced fear after confronting phobias in their sleep

         
       
  • Contact us
  • Privacy policy
  • Terms and Conditions
[Do not sell my information]

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

Subscribe
  • My Account
  • Cognitive Science Research
  • Mental Health Research
  • Social Psychology Research
  • Drug Research
  • Relationship Research
  • About PsyPost
  • Contact
  • Privacy Policy